Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$53.77 USD
-1.83 (-3.29%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $53.79 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 161 - 180 ( 313 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Time Likes Omecamtiv, So Do KOLs;Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Forward Progress Continues; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2015 Results; Firing on All Cylinders and Lots Happening This Year
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
"Vision 2020" and Our Vision is 20/20 on Omecamtiv Next Steps
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Importance of SVC Garners Further Support for VITALITY-ALS
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
''107 SMA Program Underway with Astellas; COPD Study to Follow
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Numbers Are COSMIC; Nice Win for CYTK and AMGN; Target to $22
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
KOL Panel Highlight; "Drug Is Doing Something Completely Different"
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Talk About Instant Gratification; Going COSMIC This Weekend
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q15 Results; Perspective is Key; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J